Welcome to our dedicated page for Bicara Therapeutics SEC filings (Ticker: BCAX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page compiles U.S. Securities and Exchange Commission (SEC) filings for Bicara Therapeutics Inc. (NASDAQ: BCAX), a clinical-stage biopharmaceutical company developing the bifunctional antibody ficerafusp alfa for solid tumors. As a public issuer, Bicara submits periodic and current reports that provide detail on its financial position, research and development spending, and key clinical and corporate events.
Among the filings available for review are Form 10-K annual reports and Form 10-Q quarterly reports, which describe operating expenses, including research and development and general and administrative costs, as well as cash, cash equivalents, and investments. These documents give insight into how Bicara funds the pivotal FORTIFI-HN01 trial in recurrent/metastatic head and neck squamous cell carcinoma and its Phase 1/1b expansion cohorts in head and neck cancer and metastatic colorectal cancer.
Form 8-K current reports, such as those referenced in the provided data, furnish press releases on quarterly financial results and business updates. These filings often summarize recent clinical milestones for ficerafusp alfa, including dose-optimization progress, expansion cohort data, and regulatory developments like Breakthrough Therapy Designation from the U.S. Food and Drug Administration.
Investors can also use this page to access exhibits attached to Bicara’s SEC filings, which may include detailed financial statements, risk factor discussions, and other disclosures relevant to evaluating a clinical-stage biotechnology company. Stock Titan enhances these filings with AI-powered summaries that highlight key points from lengthy reports, helping readers quickly identify information on operating expenses, cash runway, clinical trial status, and other factors that influence the outlook for BCAX.
Bicara Therapeutics is offering $150,000,000 of its common stock, subject to completion and the underwriters' 30-day option to purchase up to an additional $22,500,000 of shares.
The prospectus supplement states a reference market price of
Proceeds are intended to fund regulatory and commercial readiness and continued development and manufacturing of ficerafusp alfa, including Phase 2/3 and dosing-schedule work, and for general corporate purposes; the offering economics and net proceeds per share are shown in the prospectus supplement.
Bicara Therapeutics Inc. reported new preliminary Phase 1b data for its lead drug candidate ficerafusp alfa in first-line HPV-negative recurrent/metastatic head and neck squamous cell carcinoma, using a higher 2000mg every‑other‑week dose combined with pembrolizumab.
The 2000mg Q2W regimen showed a confirmed overall response rate of 48%, including 26% complete responses, and 77% of responders had deep responses with at least 80% tumor shrinkage. Safety was generally consistent with prior experience. Bicara plans to pursue a loading and every‑three‑week maintenance regimen, while its pivotal FORTIFI‑HN01 trial continues with a 1500mg weekly schedule, supported by Breakthrough Therapy Designation in this setting.
Vestal Point Capital and its chief investment officer, Ryan Wilder, disclosed a passive ownership stake in Bicara Therapeutics Inc. They report beneficial ownership of 3,575,000 shares of Bicara common stock, representing 6.5% of the class.
The percentage is based on 54,781,950 shares outstanding as of November 5, 2025, as cited from Bicara’s Form 10-Q. The shares are held through a Vestal Point fund and a managed account, which have the right to receive dividends and sale proceeds. The filing states the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Bicara.
T. Rowe Price Investment Management, Inc. reported a passive ownership stake in Bicara Therapeutics Inc. common stock. The firm beneficially owns 3,236,595 shares, representing 5.9% of the outstanding common stock as of December 31, 2025.
T. Rowe Price has sole power to vote and dispose of these 3,236,595 shares and no shared voting or dispositive power. The firm certifies the shares were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of Bicara Therapeutics.
Deep Track Capital and affiliated entities report a 5.02% passive stake in Bicara Therapeutics Inc. common stock. They beneficially own 2,750,000 shares of Bicara’s common stock, with shared power to vote and dispose of all such shares and no sole voting or dispositive power.
The reported ownership percentage is calculated using 54,781,850 shares outstanding as of November 5, 2025, as disclosed by Bicara. The filing is made on a Schedule 13G basis, and the filers certify that the shares were not acquired to change or influence control of the company.
FMR LLC has filed an amended ownership report showing beneficial ownership of 3,347,223 shares of Bicara Therapeutics Inc. common stock, representing 6.1% of the class as of December 31, 2025.
FMR reports sole voting power over 3,346,671 shares and sole dispositive power over 3,347,223 shares. Abigail P. Johnson is also listed as a reporting person with sole dispositive power over 3,347,223 shares and no voting power. The filing notes that one or more other persons may have rights to dividends or sale proceeds, but no such person holds more than 5% of the outstanding common stock. The reporters certify the shares are not held to change or influence control of Bicara Therapeutics.
Bicara Therapeutics Inc. reported that President and COO, and director, Ryan Cohlhepp received a stock option award. The option gives him the right to buy 300,000 shares of common stock at an exercise price of $16.76 per share, granted on February 2, 2026.
The option expires on February 2, 2036 and vests in sixteen equal quarterly installments after February 2, 2026, as long as he continues serving the company on each vesting date. Following this grant, he beneficially owns 300,000 derivative securities directly.
Bicara Therapeutics Inc. reported that Chief Executive Officer and director Claire Mazumdar received a grant of stock options. On February 2, 2026, she was awarded options to purchase 450,000 shares of Bicara common stock at an exercise price of $16.76 per share.
The options vest in sixteen equal quarterly installments after February 2, 2026, and each vesting date requires her continued service with the company. Following this grant, she holds 450,000 stock options directly.
Bicara Therapeutics Inc. reported a new stock option grant to its Chief Medical Officer, David Raben. On February 2, 2026, he received a stock option covering 100,000 shares of common stock at an exercise price of $16.76 per share, expiring on February 2, 2036.
The shares underlying this option vest in sixteen equal quarterly installments following February 2, 2026, and each installment requires his continued service on the vesting date. Following this grant, he beneficially owns 100,000 derivative securities directly.
Bicara Therapeutics reported that its Chief Financial Officer, Hyep Ivan, received a grant of stock options on February 2, 2026. The award covers 125,000 stock options, each allowing the purchase of one share of common stock at an exercise price of $16.76 per share.
The options vest in sixteen equal quarterly installments after February 2, 2026, and require the CFO’s continued service on each vesting date. Following this grant, the reporting person beneficially owns 125,000 derivative securities directly.